Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9254 |
Name | mast-cell leukemia |
Definition | A leukemia that results_in an overwhelming number of tissue mast cells located_in peripheral blood. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia mast-cell leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
KIT V560G KIT D816V | Dasatinib | mast-cell leukemia | sensitive | detail... |
KIT V560G KIT D816V | Ponatinib | mast-cell leukemia | sensitive | detail... |
KIT V560G KIT D816V | BPR1J373 | mast-cell leukemia | sensitive | detail... |
KIT S476I | Midostaurin | mast-cell leukemia | predicted - sensitive | detail... |
KIT S476I | Nilotinib | mast-cell leukemia | predicted - sensitive | detail... |
KIT V560G KIT D816V | Avapritinib | mast-cell leukemia | sensitive | detail... |
KIT V560G | Avapritinib | mast-cell leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02415608 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | Terminated | USA | 0 |
NCT03214666 | Phase Ib/II | GTB-3550 TriKE | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Terminated | USA | 0 |
NCT03580655 | Phase II | Avapritinib | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | Active, not recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUT | 0 |
NCT04996875 | Phase II | PLX9486 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 0 |
NCT05609942 | Phase Ib/II | Elenestinib Azacitidine + Elenestinib | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) | Recruiting | USA | NOR | NLD | FRA | ESP | DEU | BEL | 0 |